Donald P. Lawrence

29.9k total citations · 4 hit papers
161 papers, 8.9k citations indexed

About

Donald P. Lawrence is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Donald P. Lawrence has authored 161 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 77 papers in Molecular Biology and 27 papers in Immunology. Recurrent topics in Donald P. Lawrence's work include Cancer Immunotherapy and Biomarkers (72 papers), Melanoma and MAPK Pathways (59 papers) and CAR-T cell therapy research (43 papers). Donald P. Lawrence is often cited by papers focused on Cancer Immunotherapy and Biomarkers (72 papers), Melanoma and MAPK Pathways (59 papers) and CAR-T cell therapy research (43 papers). Donald P. Lawrence collaborates with scholars based in United States, Canada and Australia. Donald P. Lawrence's co-authors include Ryan J. Sullivan, Keith T. Flaherty, F. Stephen Hodi, Justine V. Cohen, David F. McDermott, Alexander T. Faje, Kerry L. Reynolds, Omid Hamid, Riley Fadden and Igor Puzanov and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Donald P. Lawrence

154 papers receiving 8.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

2018 1.1k citations Justine V. Cohen, Kerry L. Reynolds et al. profile →
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

2012 826 citations Omid Hamid, Donald P. Lawrence et al. profile →
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

2010 574 citations Andrea Boni, Alexandria P. Cogdill et al. Cancer Research profile →
High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

2018 348 citations Donald P. Lawrence, Keith T. Flaherty et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald P. Lawrence United States	44	6.7k	3.1k	2.1k	1.8k	695	161	8.9k
David S. Schrump United States	55	2.8k 0.4×	4.0k 1.3×	1.9k 0.9×	1.8k 1.0×	274 0.4×	194	8.8k
Helen Gogas Greece	49	6.5k 1.0×	3.8k 1.2×	2.2k 1.1×	1.1k 0.6×	279 0.4×	330	9.2k
Jung Ho Kim South Korea	39	3.4k 0.5×	1.7k 0.6×	1.1k 0.5×	1.1k 0.6×	318 0.5×	151	6.7k
Francesco Bertolini Italy	57	4.2k 0.6×	5.0k 1.6×	1.5k 0.7×	1.2k 0.7×	1.6k 2.3×	244	10.5k
Hans Prenen Belgium	41	4.0k 0.6×	2.6k 0.8×	1.3k 0.6×	2.6k 1.5×	244 0.4×	207	8.6k
Peter Birner Austria	49	4.0k 0.6×	3.3k 1.0×	1.2k 0.6×	2.1k 1.2×	1.1k 1.6×	169	9.0k
Siqing Fu United States	51	4.1k 0.6×	3.8k 1.2×	954 0.5×	2.4k 1.4×	688 1.0×	412	9.6k
Patrick G. Morris United States	33	2.8k 0.4×	1.6k 0.5×	684 0.3×	889 0.5×	535 0.8×	136	5.2k
Ronit Simantov United States	36	3.3k 0.5×	5.5k 1.7×	1.4k 0.7×	4.3k 2.4×	370 0.5×	88	11.2k
Sonja Zweegman Netherlands	55	4.6k 0.7×	5.1k 1.6×	1.5k 0.7×	437 0.2×	1.5k 2.2×	334	10.4k

Countries citing papers authored by Donald P. Lawrence

Since Specialization

Citations

This map shows the geographic impact of Donald P. Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald P. Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald P. Lawrence more than expected).

Fields of papers citing papers by Donald P. Lawrence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald P. Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald P. Lawrence. The network helps show where Donald P. Lawrence may publish in the future.

Co-authorship network of co-authors of Donald P. Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of Donald P. Lawrence. A scholar is included among the top collaborators of Donald P. Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald P. Lawrence. Donald P. Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buchbinder, Elizabeth I., Justine V. Cohen, Giuseppe Tarantino, et al.. (2024). A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Research Communications. 4(5). 1321–1327. 7 indexed citations

Straburzyńska‐Migaj, Ewa, Michele Senni, Rolf Wachter, et al.. (2023). Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study. Journal of Cardiac Failure. 30(3). 425–435. 4 indexed citations

Aggen, David H., David S. Hong, Jeffrey Clarke, et al.. (2023). Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). 517–517. 1 indexed citations

Mooradian, Meghan J., James M. Cleary, Anita Giobbie‐Hurder, et al.. (2023). Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors. Cancer. 129(12). 1904–1918. 7 indexed citations

Ham, Seokjin, Donald P. Lawrence, Justine V. Cohen, et al.. (2021). Rejection of benign melanocytic nevi by nevus-resident CD4 ⁺ T cells. Science Advances. 7(26). 9 indexed citations

Ott, Patrick A., Kathleen L. Pfaff, Evisa Gjini, et al.. (2021). Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. Journal for ImmunoTherapy of Cancer. 9(11). e003318–e003318. 12 indexed citations

Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2020). PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 11(1). 60 indexed citations

Dubey, Divyanshu, William David, Kerry L. Reynolds, et al.. (2019). Immune checkpoint inhibitor related neurologic adverse events: clinical spectrum, management and outcomes (S21.003). Neurology. 92(15_supplement). 2 indexed citations

Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815. 48 indexed citations

10.

Friedman, Adam A., Yun Xia, Lorenzo Trippa, et al.. (2017). Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research. 23(16). 4680–4692. 5 indexed citations

11.

Wu, Xinqi, Jingjing Li, Xiaoyun Liao, et al.. (2017). Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunology Research. 5(6). 446–454. 58 indexed citations

12.

Ribas, Antoni, F. Stephen Hodi, Donald P. Lawrence, et al.. (2017). KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Annals of Oncology. 28. v430–v430. 26 indexed citations

13.

Wu, Xinqi, Anita Giobbie‐Hurder, Xiaoyun Liao, et al.. (2016). VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunology Research. 4(10). 858–868. 76 indexed citations

14.

Khalil, Danny N., Michael A. Postow, Nageatte Ibrahim, et al.. (2016). An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research. 22(21). 5204–5210. 19 indexed citations

15.

Wu, Xinqi, Anita Giobbie‐Hurder, Xiaoyun Liao, et al.. (2016). Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research. 5(1). 17–28. 123 indexed citations

16.

Carvajal, Richard D., Donald P. Lawrence, Jeffrey S. Weber, et al.. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research. 21(10). 2289–2296. 97 indexed citations

17.

Lacouture, Mario E., John C. Morris, Donald P. Lawrence, et al.. (2015). Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology Immunotherapy. 64(4). 437–446. 117 indexed citations

18.

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2012). A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 18(12). 3396–3406. 197 indexed citations

19.

Boni, Andrea, Alexandria P. Cogdill, Ping Dang, et al.. (2010). Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. Cancer Research. 70(13). 5213–5219. 574 indexed citations breakdown →

20.

Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2007). Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. Molecular Cancer Therapeutics. 6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact